Cargando…
Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence
BACKGROUND AND OBJECTIVE: Circadian rhythms may influence the pharmacokinetics of drugs. This study aimed to elucidate whether the pharmacokinetics of the orally administered drug sunitinib are subject to circadian variation. METHODS: We performed studies in male FVB-mice aged 8–12 weeks, treated wi...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4513224/ https://www.ncbi.nlm.nih.gov/pubmed/25647628 http://dx.doi.org/10.1007/s40262-015-0239-5 |
_version_ | 1782382611015925760 |
---|---|
author | Kloth, Jacqueline S. L. Binkhorst, Lisette de Wit, Annelieke S. de Bruijn, Peter Hamberg, Paul Lam, Mei H. Burger, Herman Chaves, Ines Wiemer, Erik A. C. van der Horst, Gijsbertus T. J. Mathijssen, Ron H. J. |
author_facet | Kloth, Jacqueline S. L. Binkhorst, Lisette de Wit, Annelieke S. de Bruijn, Peter Hamberg, Paul Lam, Mei H. Burger, Herman Chaves, Ines Wiemer, Erik A. C. van der Horst, Gijsbertus T. J. Mathijssen, Ron H. J. |
author_sort | Kloth, Jacqueline S. L. |
collection | PubMed |
description | BACKGROUND AND OBJECTIVE: Circadian rhythms may influence the pharmacokinetics of drugs. This study aimed to elucidate whether the pharmacokinetics of the orally administered drug sunitinib are subject to circadian variation. METHODS: We performed studies in male FVB-mice aged 8–12 weeks, treated with single-dose sunitinib at six dosing times. Plasma and tissue samples were obtained for pharmacokinetic analysis and to monitor messenger RNA (mRNA) expression of metabolizing enzymes and drug transporters. A prospective randomized crossover study was performed in which patients took sunitinib once daily at 8 a.m., 1 p.m., and 6 p.m at three subsequent courses. Patients were blindly randomized into two groups, which determined the sequence of the sunitinib dosing time. The primary endpoint in both studies was the difference in plasma area under the concentration–time curve (AUC) of sunitinib and its active metabolite SU12662 between dosing times. RESULTS: Sunitinib and SU12662 plasma AUC in mice followed an ~12-h rhythm as a function of administration time (p ≤ 0.04). The combined AUC from time zero to 10 h (AUC(10)) was 14–27 % higher when sunitinib was administered at 4 a.m. and 4 p.m. than at 8 a.m. and 8 p.m. Twenty-four-hour rhythms were seen in the mRNA levels of drug transporters and metabolizing enzymes. In 12 patients, sunitinib trough concentrations (C (trough)) were higher when the drug was taken at 1 p.m. or 6 p.m. than when taken at 8 a.m. (C (trough-1 p.m). 66.0 ng/mL; C (trough-6 p.m.) 58.9 ng/mL; C (trough-8 a.m.) 50.7 ng/mL; p = 0.006). The AUC was not significantly different between dosing times. CONCLUSIONS: Our results indicate that sunitinib pharmacokinetics follow an ~12-h rhythm in mice. In humans, morning dosing resulted in lower C (trough) values, probably resulting from differences in elimination. This can have implications for therapeutic drug monitoring. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40262-015-0239-5) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4513224 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-45132242015-07-24 Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence Kloth, Jacqueline S. L. Binkhorst, Lisette de Wit, Annelieke S. de Bruijn, Peter Hamberg, Paul Lam, Mei H. Burger, Herman Chaves, Ines Wiemer, Erik A. C. van der Horst, Gijsbertus T. J. Mathijssen, Ron H. J. Clin Pharmacokinet Original Research Article BACKGROUND AND OBJECTIVE: Circadian rhythms may influence the pharmacokinetics of drugs. This study aimed to elucidate whether the pharmacokinetics of the orally administered drug sunitinib are subject to circadian variation. METHODS: We performed studies in male FVB-mice aged 8–12 weeks, treated with single-dose sunitinib at six dosing times. Plasma and tissue samples were obtained for pharmacokinetic analysis and to monitor messenger RNA (mRNA) expression of metabolizing enzymes and drug transporters. A prospective randomized crossover study was performed in which patients took sunitinib once daily at 8 a.m., 1 p.m., and 6 p.m at three subsequent courses. Patients were blindly randomized into two groups, which determined the sequence of the sunitinib dosing time. The primary endpoint in both studies was the difference in plasma area under the concentration–time curve (AUC) of sunitinib and its active metabolite SU12662 between dosing times. RESULTS: Sunitinib and SU12662 plasma AUC in mice followed an ~12-h rhythm as a function of administration time (p ≤ 0.04). The combined AUC from time zero to 10 h (AUC(10)) was 14–27 % higher when sunitinib was administered at 4 a.m. and 4 p.m. than at 8 a.m. and 8 p.m. Twenty-four-hour rhythms were seen in the mRNA levels of drug transporters and metabolizing enzymes. In 12 patients, sunitinib trough concentrations (C (trough)) were higher when the drug was taken at 1 p.m. or 6 p.m. than when taken at 8 a.m. (C (trough-1 p.m). 66.0 ng/mL; C (trough-6 p.m.) 58.9 ng/mL; C (trough-8 a.m.) 50.7 ng/mL; p = 0.006). The AUC was not significantly different between dosing times. CONCLUSIONS: Our results indicate that sunitinib pharmacokinetics follow an ~12-h rhythm in mice. In humans, morning dosing resulted in lower C (trough) values, probably resulting from differences in elimination. This can have implications for therapeutic drug monitoring. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40262-015-0239-5) contains supplementary material, which is available to authorized users. Springer International Publishing 2015-02-03 2015 /pmc/articles/PMC4513224/ /pubmed/25647628 http://dx.doi.org/10.1007/s40262-015-0239-5 Text en © The Author(s) 2015 https://creativecommons.org/licenses/by-nc/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Original Research Article Kloth, Jacqueline S. L. Binkhorst, Lisette de Wit, Annelieke S. de Bruijn, Peter Hamberg, Paul Lam, Mei H. Burger, Herman Chaves, Ines Wiemer, Erik A. C. van der Horst, Gijsbertus T. J. Mathijssen, Ron H. J. Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence |
title | Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence |
title_full | Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence |
title_fullStr | Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence |
title_full_unstemmed | Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence |
title_short | Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence |
title_sort | relationship between sunitinib pharmacokinetics and administration time: preclinical and clinical evidence |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4513224/ https://www.ncbi.nlm.nih.gov/pubmed/25647628 http://dx.doi.org/10.1007/s40262-015-0239-5 |
work_keys_str_mv | AT klothjacquelinesl relationshipbetweensunitinibpharmacokineticsandadministrationtimepreclinicalandclinicalevidence AT binkhorstlisette relationshipbetweensunitinibpharmacokineticsandadministrationtimepreclinicalandclinicalevidence AT dewitanneliekes relationshipbetweensunitinibpharmacokineticsandadministrationtimepreclinicalandclinicalevidence AT debruijnpeter relationshipbetweensunitinibpharmacokineticsandadministrationtimepreclinicalandclinicalevidence AT hambergpaul relationshipbetweensunitinibpharmacokineticsandadministrationtimepreclinicalandclinicalevidence AT lammeih relationshipbetweensunitinibpharmacokineticsandadministrationtimepreclinicalandclinicalevidence AT burgerherman relationshipbetweensunitinibpharmacokineticsandadministrationtimepreclinicalandclinicalevidence AT chavesines relationshipbetweensunitinibpharmacokineticsandadministrationtimepreclinicalandclinicalevidence AT wiemererikac relationshipbetweensunitinibpharmacokineticsandadministrationtimepreclinicalandclinicalevidence AT vanderhorstgijsbertustj relationshipbetweensunitinibpharmacokineticsandadministrationtimepreclinicalandclinicalevidence AT mathijssenronhj relationshipbetweensunitinibpharmacokineticsandadministrationtimepreclinicalandclinicalevidence |